Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies November 10, 2025
Dispatch Bio Announces Clinical Supply and Collaboration Agreement with BMS in Solid Tumors November 10, 2025
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 in “NEO-CYT” trial in High-Risk, Surgically Resectable Neoadjuvant Stage III Melanoma November 10, 2025
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors November 10, 2025
Kelonia Therapeutics Enters into Strategic Collaboration with Johnson & Johnson to Advance in vivo CAR-T Therapies November 9, 2025
Tubulis announces Series C funding of €344M (US $401M) to initiate pivotal trials with lead ADC candidate TUB-040 November 4, 2025
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development November 4, 2025
Citius Oncology Signs US Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch November 4, 2025
Myrio Therapeutics, University of Pennsylvania, and NYU Langone Health to develop next gen solid tumor T cell immunotherapeutics November 4, 2025
Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers November 4, 2025
Takeda enters a license and collaboration agreement with Innovent Biologics for IBI363 and IBI343 October 29, 2025
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer October 29, 2025
Galapagos NV to wind down cell therapy business and pursue business development transactions October 29, 2025
Kura Oncology Receives $30M Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin October 29, 2025
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline October 29, 2025
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million October 29, 2025
Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty October 29, 2025
Hansoh Pharma signs a licence agreement worth up to $1.45B with Roche for an investigational treatment of CRC and other solid tumours October 21, 2025
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ October 21, 2025
